SCHEMBL3011194

SCHEMBL3011194

Cc1ccc(C)c(-c2csc(N3CCN(S(=O)(=O)c4cccc(Br)c4)CC3)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.56
LMNA P02545 5/20 0.47
USP2 O75604 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NFKB1 P19838 3/20 0.47
NFKB2 Q00653 3/20 0.47
RELA Q04206 3/20 0.47
MAPT P10636 5/20 0.47
HSD17B10 Q99714 2/20 0.47
RECQL P46063 1/20 0.47
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GBA1 P04062 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004123 0.90 MAPT (0.48) ARLMNAUSP2L3MBTL1MAPT
SCHEMBL3007683 0.89 AR (0.59) ARLMNAUSP2L3MBTL1NFKB1
SCHEMBL3018393 0.89 AR (0.56) ARLMNAUSP2L3MBTL1NFKB1
SCHEMBL3016700 0.89 AR (0.56) ARLMNAUSP2L3MBTL1NFKB1
SCHEMBL3010696 0.87 MAPT (0.47) ARLMNAUSP2L3MBTL1MAPT
SCHEMBL3014041 0.87 ALDH1A1 (0.59) LMNAUSP2L3MBTL1MAPTHSD17B10
SCHEMBL3014924 0.87 AR (0.64) ARLMNAUSP2L3MBTL1NFKB1
SCHEMBL3015258 0.86 MAPT (0.57) LMNAUSP2L3MBTL1MAPTHSD17B10
SCHEMBL3015048 0.86 MAPT (0.48) LMNAUSP2L3MBTL1MAPTHSD17B10
SCHEMBL3013001 0.86 MAPT (0.49) LMNAUSP2L3MBTL1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885LMNA 80/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.